246 related articles for article (PubMed ID: 24602808)
21. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.
Shimazaki T; Iijima M; Chaki S
Eur J Pharmacol; 2006 Aug; 543(1-3):63-7. PubMed ID: 16843459
[TBL] [Abstract][Full Text] [Related]
22. Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization.
Iijima M; Chaki S
Pharmacol Biochem Behav; 2005 Dec; 82(4):652-7. PubMed ID: 16359723
[TBL] [Abstract][Full Text] [Related]
23. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.
Salomé N; Stemmelin J; Cohen C; Griebel G
Psychopharmacology (Berl); 2006 Aug; 187(2):237-44. PubMed ID: 16779555
[TBL] [Abstract][Full Text] [Related]
24. QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice.
Kurhe Y; Mahesh R; Devadoss T
Biochem Biophys Res Commun; 2015 Jan; 456(1):74-9. PubMed ID: 25446100
[TBL] [Abstract][Full Text] [Related]
25. Vasopressin antagonists as anxiolytics and antidepressants: recent developments.
Simon NG; Guillon C; Fabio K; Heindel ND; Lu SF; Miller M; Ferris CF; Brownstein MJ; Garripa C; Koppel GA
Recent Pat CNS Drug Discov; 2008 Jun; 3(2):77-93. PubMed ID: 18537767
[TBL] [Abstract][Full Text] [Related]
26. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
[TBL] [Abstract][Full Text] [Related]
27. Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice.
Amikishieva AV; Ilnitskaya SI; Nikolin VP; Popova NA
Exp Oncol; 2011 Sep; 33(3):126-9. PubMed ID: 21956463
[TBL] [Abstract][Full Text] [Related]
28. The effects of a standardized Acanthopanax koreanum extract on stress-induced behavioral alterations in mice.
Jung JM; Park SJ; Lee YW; Lee HE; Hong SI; Lew JH; Hong E; Shim JS; Cheong JH; Ryu JH
J Ethnopharmacol; 2013 Jul; 148(3):826-34. PubMed ID: 23721913
[TBL] [Abstract][Full Text] [Related]
29. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
Serradeil-Le Gal C; Wagnon J; Tonnerre B; Roux R; Garcia G; Griebel G; Aulombard A
CNS Drug Rev; 2005; 11(1):53-68. PubMed ID: 15867952
[TBL] [Abstract][Full Text] [Related]
30. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
31. [5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine].
Jiang XZ; Li YF; Zhang YZ; Chen HX; Li J; Wang NP
Yao Xue Xue Bao; 2008 May; 43(5):467-73. PubMed ID: 18717332
[TBL] [Abstract][Full Text] [Related]
32. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent.
Hughes ZA; Liu F; Platt BJ; Dwyer JM; Pulicicchio CM; Zhang G; Schechter LE; Rosenzweig-Lipson S; Day M
Neuropharmacology; 2008 Jun; 54(7):1136-42. PubMed ID: 18423777
[TBL] [Abstract][Full Text] [Related]
33. The Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.
Barsegyan A; Atsak P; Hornberger WB; Jacobson PB; van Gaalen MM; Roozendaal B
Neuropsychopharmacology; 2015 Jul; 40(8):1979-89. PubMed ID: 25669604
[TBL] [Abstract][Full Text] [Related]
34. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A; Stachowicz K; Tatarczyńska E
Neuropharmacology; 2006 Sep; 51(3):578-86. PubMed ID: 16828124
[TBL] [Abstract][Full Text] [Related]
35. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.
Breuer ME; van Gaalen MM; Wernet W; Claessens SE; Oosting RS; Behl B; Korte SM; Schoemaker H; Gross G; Olivier B; Groenink L
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):101-6. PubMed ID: 18668225
[TBL] [Abstract][Full Text] [Related]
36. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Bespalov AY; van Gaalen MM; Sukhotina IA; Wicke K; Mezler M; Schoemaker H; Gross G
Eur J Pharmacol; 2008 Sep; 592(1-3):96-102. PubMed ID: 18634781
[TBL] [Abstract][Full Text] [Related]
37. Investigation of antidepressant-like and anxiolytic-like actions and cognitive and motor side effects of four N-methyl-D-aspartate receptor antagonists in mice.
Refsgaard LK; Pickering DS; Andreasen JT
Behav Pharmacol; 2017 Feb; 28(1):37-47. PubMed ID: 27740963
[TBL] [Abstract][Full Text] [Related]
38. Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic.
Yokoyama F; Yamauchi M; Oyama M; Okuma K; Onozawa K; Nagayama T; Shinei R; Ishikawa M; Sato Y; Kakui N
Psychopharmacology (Berl); 2009 Aug; 205(2):177-87. PubMed ID: 19357839
[TBL] [Abstract][Full Text] [Related]
39. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
Scott JD; Miller MW; Li SW; Lin SI; Vaccaro HA; Hong L; Mullins DE; Guzzi M; Weinstein J; Hodgson RA; Varty GB; Stamford AW; Chan TY; McKittrick BA; Greenlee WJ; Priestley T; Parker EM
Bioorg Med Chem Lett; 2009 Nov; 19(21):6018-22. PubMed ID: 19800231
[TBL] [Abstract][Full Text] [Related]
40. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats.
Wesołowska A; Nikiforuk A; Stachowicz K
Behav Pharmacol; 2007 Sep; 18(5-6):439-46. PubMed ID: 17762512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
